• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性髓性白血病伴罕见费城染色体变异涉及 16 号染色体。

Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16.

机构信息

Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

出版信息

Am J Case Rep. 2024 Aug 31;25:e944641. doi: 10.12659/AJCR.944641.

DOI:10.12659/AJCR.944641
PMID:39215452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11373876/
Abstract

BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome, which results from the fusion of the translocation of the ABL1 gene from chromosome 9 to the BCR gene located in chromosome 22, forming the BCR-ABL gene on chromosome number 22, which accounts for approximately 95% of CML cases. Complex translocation involving other chromosomes can occur. CASE REPORT We present a rare case of CML with a variant Ph chromosome, in which chromosome 16 was involved with the usual translocation. A 34-year-old woman presented with a history of left upper quadrant pain and excessive sweating, with no hepatosplenomegaly on examination. She was found to have leukocytosis, with elevated neutrophils (34 000/mm³), basophils (1460/mm³), and eosinophils (2650/mm³). Karyotyping showed a translocation (16;22) (q24,q11.2), and FISH analysis showed BCR-ABL fusion as a result of (9,22) translocation, with a third chromosome (chromosome 16) involved and fused with chromosome 22, with a different breakpoint, which has never been reported in the literature, affecting the long arm of chromosome 16. The patient was treated with a first-generation tyrosine kinase inhibitor (imatinib) and achieved a deep molecular remission. The repeated FISH analysis confirmed the disappearance of both translocations (9,22) and (16,22). CONCLUSIONS The impact of the additional chromosomal aberration in CML is widely heterogeneous, and the outcome is dependent on multiple factors. Larger studies are needed to clarify the outcome in CML with variant Ph chromosomes, as most of the available data come from reported cases.

摘要

背景

慢性髓性白血病(CML)是一种骨髓增生性疾病,其特征是存在费城(Ph)染色体,这是由于 9 号染色体上的 ABL1 基因易位到 22 号染色体上的 BCR 基因,形成 22 号染色体上的 BCR-ABL 基因,约占 CML 病例的 95%。也可能发生涉及其他染色体的复杂易位。

病例报告

我们报告了一例罕见的 CML 伴有变异 Ph 染色体,其中 16 号染色体参与了常见易位。一名 34 岁女性因左上象限疼痛和过度出汗就诊,体检时无肝脾肿大。她被发现白细胞增多,中性粒细胞(34,000/mm³)、嗜碱性粒细胞(1460/mm³)和嗜酸性粒细胞(2650/mm³)升高。染色体核型显示易位(16;22)(q24,q11.2),FISH 分析显示 BCR-ABL 融合是由于(9,22)易位引起的,第三条染色体(16 号染色体)与 22 号染色体融合,且有不同的断裂点,这在文献中从未报道过,影响 16 号染色体的长臂。该患者接受第一代酪氨酸激酶抑制剂(伊马替尼)治疗,达到深度分子缓解。重复 FISH 分析证实两种易位(9,22)和(16,22)均消失。

结论

CML 中额外染色体异常的影响广泛存在异质性,其结果取决于多种因素。需要更大的研究来阐明变异 Ph 染色体 CML 的结果,因为大多数可用数据来自已报道的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/792e770ea813/amjcaserep-25-e944641-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/6f6f6832d97b/amjcaserep-25-e944641-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/5988528cfd63/amjcaserep-25-e944641-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/792e770ea813/amjcaserep-25-e944641-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/6f6f6832d97b/amjcaserep-25-e944641-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/5988528cfd63/amjcaserep-25-e944641-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebe/11373876/792e770ea813/amjcaserep-25-e944641-g003.jpg

相似文献

1
Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16.慢性髓性白血病伴罕见费城染色体变异涉及 16 号染色体。
Am J Case Rep. 2024 Aug 31;25:e944641. doi: 10.12659/AJCR.944641.
2
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.CML 患者伴有涉及 7 号染色体的费城易位变异的临床和遗传特征概述:病例系列。
Leuk Res. 2021 Dec;111:106725. doi: 10.1016/j.leukres.2021.106725. Epub 2021 Oct 4.
3
Three-way Philadelphia Translocation [t(46, XX, t(9;22;16) (q34;q11.2;q24)] in Chronic Myeloid Leukemia: A Report of Two Cases with Review of the Literature.慢性髓性白血病中的三向费城易位[t(46, XX, t(9;22;16)(q34;q11.2;q24)]:两例报告并文献复习
J Cancer Res Ther. 2024 Apr 1;20(3):1066-1070. doi: 10.4103/jcrt.jcrt_274_21. Epub 2024 Jan 22.
4
The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia.首例慢性髓性白血病患者的 t(4;7;9;22;8;14)六向复杂易位。
J Hematop. 2024 Jun;17(2):97-101. doi: 10.1007/s12308-024-00577-8. Epub 2024 Mar 16.
5
Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.一例伴有四向 Ph 染色体易位和 BCR/ABL 基因突变的 CML 患者在伊马替尼治疗失败后用尼罗替尼获得成功治疗。
Int J Hematol. 2011 Feb;93(2):243-246. doi: 10.1007/s12185-011-0769-z. Epub 2011 Feb 1.
6
A Rare Case of X-Linked Four-Way Philadelphia Chromosome Translocation with Therapeutic Challenges and Clonal Evolution.一例罕见的 X 连锁四向费城染色体易位伴治疗挑战和克隆进化。
Clin Lab. 2024 Sep 1;70(9). doi: 10.7754/Clin.Lab.2024.240323.
7
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.白血病细胞系:用于研究费城染色体阳性白血病的体外模型。
Leuk Res. 1999 Mar;23(3):207-15. doi: 10.1016/s0145-2126(98)00171-4.
8
A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature.一例新诊断的慢性期慢性髓性白血病患者中独特的三向费城染色体变异t(4;9;22)(q21;q34;q11.2):病例报告及文献复习
J Med Case Rep. 2021 May 25;15(1):285. doi: 10.1186/s13256-021-02885-4.
9
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.复杂染色体重排可能会将bcr/abl融合基因位点定位在22q11以外的位置。
Haematologica. 2000 Jan;85(1):35-9.
10
A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia.一名新诊断的慢性髓性白血病患者出现t(6;9;22)(p22;q34;q11.2)复杂变异易位及der(19)的独特病例。
Cancer Genet. 2019 Sep;237:78-81. doi: 10.1016/j.cancergen.2019.06.008. Epub 2019 Jun 13.

引用本文的文献

1
Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration.利用下一代测序推进慢性髓性白血病研究:潜在益处、局限性及未来临床整合
Hum Genet. 2025 May;144(5):481-503. doi: 10.1007/s00439-025-02745-x. Epub 2025 Apr 21.

本文引用的文献

1
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.阿塞西尼布:首个BCR::ABL1激酶的变构抑制剂。
Blood Res. 2023 Apr 30;58(S1):S29-S36. doi: 10.5045/br.2023.2023017. Epub 2023 Mar 9.
2
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.EUTOS 长期生存评分可预测基于实践队列的慢性髓系白血病患者的疾病特异性死亡率和分子反应。
Cancer Med. 2020 Dec;9(23):8931-8939. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.
3
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
4
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.二代酪氨酸激酶抑制剂在伴有其他克隆染色体异常的慢性髓性白血病患者中的潜在作用:一项回顾性 CML 合作研究组分析。
Oncol Rep. 2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27.
5
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.欧洲血液系统肿瘤细胞遗传学分析的推荐意见和质量保证
Leukemia. 2019 Aug;33(8):1851-1867. doi: 10.1038/s41375-019-0378-z. Epub 2019 Jan 29.
6
Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report.尼洛替尼治疗伴t(9;22;16)(q34;q11;p13)的复发性慢性髓性白血病:一例报告
Medicine (Baltimore). 2018 Oct;97(42):e12875. doi: 10.1097/MD.0000000000012875.
7
Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.慢性髓性白血病对靶向治疗的耐药机制
Handb Exp Pharmacol. 2018;249:231-250. doi: 10.1007/164_2017_81.
8
A rare case of three-way complex variant translocation in chronic myeloid leukemia t(6;9;22)(p21;q34;q11): A case report.慢性髓性白血病中罕见的三方复杂变异易位t(6;9;22)(p21;q34;q11):一例报告
Biomed Rep. 2017 Oct;7(4):377-379. doi: 10.3892/br.2017.967. Epub 2017 Aug 17.
9
The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.变异型费城染色体易位对慢性髓性白血病临床病程的影响
Turk J Haematol. 2016 Mar 5;33(1):60-5. doi: 10.4274/tjh.2015.0237.
10
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.10 年期间伊马替尼治疗 CML 的安全性和疗效:来自随机 CML 研究 IV 的数据。
Leukemia. 2015 May;29(5):1123-32. doi: 10.1038/leu.2015.36. Epub 2015 Feb 13.